SciClone Pharmaceuticals IPO: Valuation Insights
SciClone has launched its IPO to raise net proceeds of $252m, at the mid-point of the price range. We recommend a pass as our concerns on the...
1k Views
Luye Pharma (2186.HK) - Could the Magic of Hillhouse Last Long?
This article analyzed Luye Pharma after the subscription agreement with Hillhouse in terms of the past performance, insights on recent changes, and...
371 Views
HK Shorts: Squeeze-O-Meter
Following the GameStop saga, we try to identify stocks in HK that could be susceptible to a short squeeze based on short interest vs issued shares...
1.3k Views
Innovent Biologics Placement - Momentum Is Very Strong but past Deals Have Been Mixed
Innovent Biologics Inc (1801 HK) is looking to raise about U$600m to fund its clinical trials and product licensing and possible M&A. This will be...
545 Views
Pre-IPO Bio-Thera Solutions - Insights on Pipeline and the Competitive Landscape
This article summarized the insights on major products of Bio-Thera Solutions in the pipeline and related competitive landscape with other key...
462 Views